Erin Iturriaga

TL;DR: Among patients with stable atherosclerosis, low‐dose methotrexate did not reduce levels of interleukin‐1β, interleUKin‐6, or C‐reactive protein and did not result in fewer cardiovascular events than placebo and was associated with elevations in liver‐enzyme levels, reductions in leukocyte counts and hematocrit levels, and a higher incidence of non–basal‐cell skin cancers than placebo.

TL;DR: Genotype-guided selection of an oral P2Y12 inhibitor, compared with conventional clopidogrel therapy without point-of-care genotyping, resulted in no statistically significant difference in a composite end point of cardiovascular death, myocardial infarction, stroke, stent thrombosis, and severe recurrent ischemia.

TL;DR: The current state of the art for digital clinical trials is described, including defining and outlining the composition and elements of digital trials, and describing recruitment and retention using digital technology.

TL;DR: TAILOR-PCI (Tailored Antiplatelet Initiation to Lessen Outcomes due to Decreased Clopidogrel Response After Percutaneous Coronary Intervention) is a large, pragmatic, randomized trial comparing point- of-care genotype-guided antiplatelet therapy with routine care to determine whether identifying CYP2C19 loss-of-function allele patients prospectively and prescribing alternative antiplatelets therapy is beneficial.

TL;DR: This review presents information on the cardiovascular health of justice-involved populations, and unique prevention and care conditions in correctional facilities, and proposes promising areas for research to improve the cardiovascularHealth of this population.